UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

Health technology assessment (Winchester, England), 2006-07, Vol.10 (23), p.iii-iv

2006

Volltextzugriff (PDF)

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Health technology assessment (Winchester, England), 2006-09, Vol.10 (31), p.iii-iv

2006

Volltextzugriff (PDF)

Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses

Health technology assessment (Winchester, England), 2007-08, Vol.11 (29), p.1-226

2007

Volltextzugriff (PDF)

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Value in health, 2014-11, Vol.17 (7), p.A399-A399

2014

Volltextzugriff (PDF)

UPDATE OF THE MODEL VALIDATION OF THE ECONOMIC AND HEALTH OUTCOMES MODEL OF TYPE 2 DIABETES MELLITUS (ECHO-T2DM)

Value in health, 2016-05, Vol.19 (3), p.A88-A88

2016

Volltextzugriff (PDF)

Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling

Value in health, 2014-11, Vol.17 (7), p.A400-A400

2014

Volltextzugriff (PDF)

Cost-Effectiveness of Sequences of Biologic Treatments for Moderate-To-Severe Psoriasis in Finland

Value in health, 2013-11, Vol.16 (7), p.A507-A508

2013

Volltextzugriff (PDF)

FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A434-A434

2013

Volltextzugriff (PDF)

Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - with model applications for Denmark, Norway and Finland

Journal of the European Academy of Dermatology and Venereology, 2010-04, Vol.24 (4), p.474-480

2010

Volltextzugriff (PDF)

Current and Future Strategy for Osteoporosis Screening and Diagnostics: Cost-Effectiveness of Frax with or without Pulse-Echo Ultrasound Measurement of Bone Mineral Density and DXA on Demand

Value in health, 2013-11, Vol.16 (7), p.A564-A565

2013

Volltextzugriff (PDF)

PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland

Value in health, 2012-11, Vol.15 (7), p.A454-A454

2012

Volltextzugriff (PDF)

Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis

Heart (British Cardiac Society), 2007-10, Vol.93 (10), p.1238-1243

2007

Volltextzugriff (PDF)

PRM140 - Correctly Capturing Uncertainty in Treatment Effects in Simulation Modeling

Value in health, 2016-11, Vol.19 (7), p.A382-A382

2016

Volltextzugriff (PDF)

Correctly Capturing Uncertainty in Treatment Effects in Simulation Modeling

Value in health, 2016-11, Vol.19 (7), p.A382-A382

2016

Volltextzugriff (PDF)

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis

Rheumatology (Oxford, England), 2007-11, Vol.46 (11), p.1729-1735

2007

Volltextzugriff (PDF)

PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

Value in health, 2019-11, Vol.22, p.S590-S590

2019

Volltextzugriff (PDF)

POSA69 Coffee Drinking in Finland: Is It Value for Money? Cost-Effectiveness with User Interface Modelling

Value in health, 2022-01, Vol.25 (1), p.S46-S46

2022

Volltextzugriff (PDF)

PCV70 Cost Effectiveness of Ticagrelor in the Treatment of Acute Coronary Syndrome in Germany

Value in health, 2011, Vol.14 (7), p.A376-A377

2011

Volltextzugriff (PDF)

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model

PloS one, 2012-08, Vol.7 (8), p.e42003-e42003

2012

Volltextzugriff (PDF)

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

Value in health, 2023-12, Vol.26 (12), p.S120

2023

Volltextzugriff (PDF)

EE130 Digital Remote Monitoring of Intravenous Infusions Frees Capacity and Saves Materials: Economic Evaluation Study in Finland

Value in health, 2022-07, Vol.25 (7), p.S359-S360

2022

Volltextzugriff (PDF)

(859) - Treatment Patterns for Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 - A Descriptive Real-World Cohort Study (FINPAH)

The Journal of heart and lung transplantation, 2024-04, Vol.43 (4), p.S407-S407

2024

Volltextzugriff (PDF)

POSC140 Value Assessment Modelling of Fingenious® Recall Service for Clinical Trials

Value in health, 2022-01, Vol.25 (1), p.S114-S115

2022

Volltextzugriff (PDF)

CO131 Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in Finland (FINPAH) – A Descriptive Retrospective Real World Cohort Study Between 2008 and 2020

Value in health, 2022-12, Vol.25 (12), p.S43-S43

2022

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(48)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

UPDATE OF THE MODEL VALIDATION OF THE ECONOMIC AND HEALTH OUTCOMES MODEL OF TYPE 2 DIABETES MELLITUS (ECHO-T2DM)

Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling

Cost-Effectiveness of Sequences of Biologic Treatments for Moderate-To-Severe Psoriasis in Finland

FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland

Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - with model applications for Denmark, Norway and Finland

Current and Future Strategy for Osteoporosis Screening and Diagnostics: Cost-Effectiveness of Frax with or without Pulse-Echo Ultrasound Measurement of Bone Mineral Density and DXA on Demand

PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland

Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis

PRM140 - Correctly Capturing Uncertainty in Treatment Effects in Simulation Modeling

Correctly Capturing Uncertainty in Treatment Effects in Simulation Modeling

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis

PDB95 RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

POSA69 Coffee Drinking in Finland: Is It Value for Money? Cost-Effectiveness with User Interface Modelling

PCV70 Cost Effectiveness of Ticagrelor in the Treatment of Acute Coronary Syndrome in Germany

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

EE130 Digital Remote Monitoring of Intravenous Infusions Frees Capacity and Saves Materials: Economic Evaluation Study in Finland

(859) - Treatment Patterns for Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 - A Descriptive Real-World Cohort Study (FINPAH)

POSC140 Value Assessment Modelling of Fingenious® Recall Service for Clinical Trials

CO131 Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in Finland (FINPAH) – A Descriptive Retrospective Real World Cohort Study Between 2008 and 2020

Suchergebnisse filtern